Icon plc Stock
Price
Target price
€149.10
€149.10
4.020%
5.75
4.020%
€204.41
31.10.25 / Tradegate
WKN: 932242 / Symbol: ICLR / Name: ICON / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Icon plc Stock
Icon plc dominated the market today, gaining €5.75 (4.020%).
With 22 Buy predictions and not a single Sell prediction Icon plc is an absolute favorite of our community.
With a target price of 204 € there is a positive potential of 36.82% for Icon plc compared to the current price of 149.1 €.
Pros and Cons of Icon plc in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Icon plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Icon plc | 4.020% | -2.708% | -9.472% | -26.696% | -27.445% | -23.929% | - |
| Alkermes plc | -0.750% | 2.326% | 0.000% | 9.091% | -5.714% | 14.385% | 91.304% |
| Ironwood Pharmaceuticals | 0.000% | -7.971% | -3.053% | -66.043% | -69.762% | -88.675% | -84.790% |
| Novocure Ltd | -0.050% | -5.927% | -7.378% | -25.586% | -61.848% | -85.007% | -88.477% |
Comments
Icon (NASDAQ:ICLR) was upgraded by analysts at Rothschild & Co Redburn from a "neutral" rating to a "buy" rating. They now have a $236.00 price target on the stock.
Show more
Ratings data for ICLR provided by MarketBeat
Icon (NASDAQ:ICLR) had its price target raised by analysts at Robert W. Baird from $222.00 to $224.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for ICLR provided by MarketBeat
Icon Plc (NASDAQ: ICLR) was upgraded by analysts at Baird R W from a "hold" rating to a "strong-buy" rating.
Show more
Ratings data for ICLR provided by MarketBeat
News
3 Healthcare Pathbreakers With Long-Term Tailwinds
In the world of healthcare stocks, a major innovation, new medical device, or successful drug treatment can cement a firm's position as a leader. Unfortunately, many firms chase after these goals
LVM Capital Management Dumps 16,000 ICON Public Shares Worth $2.6 million
According to an SEC filing dated July 2, 2025, LVM Capital Management reduced its position in ICON Public Limited (NASDAQ:ICLR) by selling 16,096 shares. The transaction was valued at $2.58 million
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the
